cancer

A team of scientists led by the University Hospital Zurich (Switzerland) has tested a new treatment for glioblastoma, a highly aggressive nervous system tumour with a poor prognosis. The therapy consists of a fusion protein that combines the TNF factor - a key factor in the processes of inflammation and immune response - with an antibody that targets the tumour matrix. The researchers, whose results are published in the journal Science Translational Medicine, have studied its action together with a type of chemotherapy both in mice and in six patients included in a phase 1 clinical trial.

Most high-income countries do not have prostate cancer screening programmes for their entire population; prostate-specific antigen (PSA) tests can be done on an individual basis. In an opinion piece published in The BMJ, a group of urologists and epidemiologists specialised in prostate cancer screening argue for restricting the use of PSA tests to avoid over-detection and over-treatment. 

A phase 1 clinical trial has tested personalised mRNA vaccines against the most common type of pancreatic cancer with a particularly poor prognosis. The treatment, which is tailored to the characteristics of each patient's tumour, was given to 16 people along with surgery, chemotherapy and other immunotherapy. Half of them showed an immune response to the vaccine, which was associated with a better prognosis. The results are published in the journal Nature.

A study published in JAMA Network Open has followed 1,340 women with high-risk operable breast cancer. Analysing their lifestyles before, during and after treatment, the researchers conclude that those who followed a healthier pattern - including physical activity, no smoking, high fruit and vegetable intake, and low consumption of meat and sugary drinks - had a 37% lower risk of relapse and a 58% higher chance of survival than those who followed a worse pattern. Although the improvements in absolute risk were much smaller, the authors conclude that "lifestyle interventions may be a safe, inexpensive and feasible adjuvant strategy to delay and prevent recurrence and death from the world's most common cancer".

A study published today in the NEJM examines the risk of relapse in breast cancer patients who decide to pause endocrine therapy to try to become pregnant. The results show that temporarily stopping treatment does not confer an increased risk in the long term, but the authors warn of the need for further follow-up.

A phase 2 clinical trial has analysed the safety and efficacy of adding immunotherapy to traditional chemotherapy to treat a subtype of acute lymphoblastic leukaemia in children under one year of age. This subtype of leukaemia, although rare in absolute terms, is the most common in children of this age, and its prognosis in this age group had not improved in recent years. The immunotherapy used, a bispecific antibody that binds to tumour cells on the one hand and T lymphocytes on the other, improved two-year survival from 66% to 93% in treated patients, according to The New England Journal of Medicine (NEJM).

A drug in gel form cured 100 percent of mice with a very aggressive brain tumor. The authors hope that this is a first step towards helping human patients with glioblastoma, one of the most dangerous brain tumors in humans. The article is published today in PNAS.

Between 10-15% of childhood brain tumours are diffuse midline gliomas, a type of tumour that occurs within the brainstem, making it almost impossible to remove surgically. Research published in Science Translational Medicine has used a type of molecule (antisense-ASO oligonucleotides) in mouse models of this tumour to slow tumour growth and prolong survival. The authors hope that the research will reach clinical trials and, in that case, the potential new treatment would be combined with others such as radiotherapy or immunotherapy with CAR-T cells.

Seven studies published in Nature and Nature Medicine look at how lung cancer evolves, with genomic studies of more than 1,600 tumour samples taken from 421 patients in the TRACERx project. The research includes the most common type of lung cancer (NSCLC) and assesses why tumours sometimes recur, spread to other parts of the body or the effects of platinum-based chemotherapy.

An international group of researchers has conducted an epidemiological study to investigate the correlation between fine particulate matter (PM2.5) air pollution and certain types of lung cancer. The authors have confirmed their findings in animal models, according to research published in Nature.